SYBX Synlogic, Inc. Return on Sales by Gross Profit

Corporate emblem and logo of synlogictx.com (SYBX)

Synlogic, Inc. (SYBX) seeks to monetize its intellectual assets through licensing and the sale of its developments. The company creates synthetic bacteria to combat gut toxins associated with rare metabolic disorders. Currently, the business is searching for a strategic partner to preserve liquidity following a restructuring. The gross margin level on this GURU.Markets chart is 0.00, which reflects the current level of the metric.

Synlogic, Inc. (SYBX): Gross Profitability from 07/04/2022 to 01/24/2026

Analytical breakdowns and data insights for company Synlogic, Inc. (SYBX)

- current quotes and average value forecast:
Basic company analysis:synlogictx.com, SYBX
Signature product of Synlogic Corp

For Synlogic, Inc. (SYBX), the efficiency of intellectual property monetization and payments from pharma behemoths directly reflects the company's ability to control direct costs. An analysis of historical gross margins allows for an assessment of the revenue share free of cost of goods sold, where sharp peaks may indicate operational overheating, creating risks for long-term capital stability and share value.